Key facts
- It has raised $28.3M; the latest was Later Stage VC ($8.4M) in Mar 2026.
- Notable investors include SBI Investment, Partners Investment, Ministry of Health and Welfare (South Korea), AJU IB Investment, Albatross Investment — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Cenyx Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Cenyx Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cenyx Biotech
Developer of a cerium oxide-based nanozyme therapeutic designed to treat acute and chronic inflammatory diseases. The company offers enzyme-mimetic nanoparticles that catalytically eliminate reactive oxygen species, enabling patients suffering from conditions such as subarachnoid hemorrhage and acute kidney injury to improve management of inflammation-related damage.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 36
- Website
- cenyxbiotech.com/
- Ownership
- Privately Held (backing)
Cenyx Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cenyx Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cenyx Biotech in its N-PORT filings yet. We sweep new filings monthly.